Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment

BackgroundRepeated radioiodine (131I) treatment (RT) are commonly performed in patients with 131I-avid distant metastatic differentiated thyroid cancer (DM-DTC), but more precise indications remain indeterminate. This prospective study was conducted to explore predictors for biochemical response (BR...

Full description

Bibliographic Details
Main Authors: Ri Sa, Lin Cheng, Yuchen Jin, Hao Fu, Yan Shen, Libo Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Endocrinology
Subjects:
thyroid cancer
radioiodine
target/background ratio
thyroglobulin
biochemical response
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2020.587315/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2020.587315/full

Similar Items